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Adaptive chemoresistance and consequent tumor recurrence presentmajor obstacles to the improvement of
the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell,
Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modu-
lating the stability of microtubules.Paclitaxel was first introduced into clinical
use during the 1990’s and became part of
the standard-of-care with carboplatin for
the up-front treatment of advanced-stage
epithelial ovarian cancer (EOC) based
upon a randomized phase III trial. Despite
the initial high response rate, almost all
patients eventually developed platinum/
taxane-resistant relapses, which resulted
in minimal improvement of overall survival
during the past 30 years. Even in the
era of genomics, predicting paclitaxel
response/resistance still remains difficult.
The molecular mechanisms underlying
adaptive paclitaxel resistance are also
largely unknown, which is partially due to
the lack of appropriate biopsy material
because surgery is rarely performed in
recurrent drug resistant ovarian cancers
(Jayson et al., 2014).
It is well established that the microtu-
bules are highly dynamic structures
orchestrating a variety of cellular pro-
cesses including cellular polarity, trans-
portation, motility, and mitosis. Paclitaxel
exerts its action by directly binding to
polymerized b-tubulin, resulting in the
formation of static microtubules. At thera-
peutic concentration, paclitaxel primarily
interferes with mitotic spindle dynamics
and triggers the mitotic checkpoint to
induce an extended G2/M arrest that
can lead to cell death via the intrinsic
(mitochondrial) apoptotic pathway (Fig-
ure 1). Several general adaptive mecha-
nisms conferring paclitaxel resistance
have been identified in tumor cells,
including the elevation of efflux mediated
by P-glycoprotein coded by the MDR-1/
ABCB1 gene, defects in spindle assembly
checkpoint, mitotic slippage, activation
of pro-survival signaling, and apoptosisevasion by modulating the activity of p53
and BCL2 family proteins (Murray et al.,
2012). In parallel, the neoplastic microtu-
bule system itself may also implicate in
paclitaxel resistance. The aberrant over-
expression of b-tubulin isotype III that
lacks the predicted paclitaxel binding
motif has been linked to paclitaxel resis-
tance and poor prognosis in various
tumor types, including serous ovarian
cancer. However, conflicting studies
suggest elevated bIII-tubulin may even
sensitize cells to paclitaxel in breast
cancer, clear cell ovarian cancer, and
melanoma (Mariani et al., 2015). Microtu-
bule binding proteins that modulate
microtubule dynamics comprise another
category of factors that may influence
resistance to paclitaxel (Bhat and Setaluri,
2007). Microtubule associated proteins
(MAPs), such as tau, MAP2, and MAP4,
in their unphosphorylated state, promote
microtubule assembly and stabilization
by conformational rearrangement of
tubulin subunits. MAP4 phosphorylation
and dissociation from microtubules has
been demonstrated to correlate with
decreased paclitaxel sensitivity in pacli-
taxel-resistant ovarian cancer cell lines
(Poruchynsky et al., 2001). Moreover,
structural evidence for cooperativemicro-
tubule stabilization by paclitaxel and
MAP4 has been provided by amide
hydrogen/deuterium exchange coupled
with mass spectrometry, further suggest-
ing the potential relationship between
MAPs and paclitaxel sensitivity (Xiao
et al., 2012). Nevertheless, the precise
role for MAPs in paclitaxel resistance
remains to be defined.
In this issue of Cancer Cell, Yu et al.
(2015) describe a new mechanism forCancer Cpaclitaxel resistance involving spleen
tyrosine kinase (SYK) in high-grade
advanced-stage ovarian cancer. SYK
is a cytoplasmic non-receptor tyrosine
kinase implicated in the physiological
and pathological development of the
lymphatic system and lymphoma, espe-
cially for the B cell lineage (Geahlen,
2014). Although the role of SYK in epithe-
lial malignancy remains to be defined,
elevated SYK expression has been
demonstrated in recurrent epithelial
ovarian tumors compared to paired pri-
mary tumors in a previous proteomics
study by the same research group (Jina-
wath et al., 2010). Notably, tumor-spe-
cific alternative splicing of SYK triggered
by EGF has been linked to mitotic spin-
dle assembly, cytokinesis, and apoptotic
evasion (Prinos et al., 2011). In this
study, Yu et al. (2015) demonstrated the
association of SYK and its active auto-
phosphorylated form p-SYK at Y525/
526 with chemoresistance in several
independent cohorts composed of
paired primary and recurrent ovarian tu-
mors. Using primary ovarian cancer cell
cultures and cell lines, the authors attrib-
uted the SYK-mediated in vitro and
in vivo chemoresistance to paclitaxel
rather than platinum. In various ovarian
cancer cell lines with different paclitaxel
sensitivities, as well as two isogenic pairs
of paclitaxel-sensitive and -resistant
SKOV3 and MPSC1 cell lines, the au-
thors have convincingly demonstrated
small molecule inhibitors to SYK and
SYK knock-down significantly enhance
paclitaxel sensitivity in various serous
and clear cell ovarian cancer cell lines.
Moreover, a synergistic effect of SYK
inhibitor R406 (an active metabolite ofell 28, July 13, 2015 ª2015 Elsevier Inc. 7
Figure 1. SYK Augments Paclitaxel Cytotoxicity by Stabilizing Microtubule Structure
Acquired paclitaxel resistance in tumor cells presents a multiplex nature. These mechanisms can be
broadly categorized as microtubule dependent and microtubule independent. Tumor cells typically
present higher stress tolerance to cytotoxic xenobiotics by overexpressing drug efflux proteins such as
ATP binding cassette transporters. Defects in mitotic checkpoints and the apoptotic pathway also
influence the resistance to paclitaxel. On the other hand, alteration of microtubule components such as
tubulin isoforms (especially bIII-tubulin/TUBB3, which has widely been evident in literature) and microtu-
bule binding proteins will directly modulate the microtubule dynamics and therefore affect paclitaxel
efficacy. In paclitaxel-resistant ovarian cancer cells, elevated activation of SYK increases the phosphor-
ylation of microtubule associated proteins MAP1B and MAP4 and attenuates their microtubule stabilizing
effect. Increased microtubule dynamics is thus suggested to counteract paclitaxel. In addition, the
SYK phosphoproteome analysis in the Yu et al. (2015) study also identified STAT3 and Akt as SYK down-
stream effectors. This observation potentially indicates the capability of SYK to induce pro-survival
signaling to alleviate paclitaxel-induced stress and warrants further investigation.
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Previewsfostamatinib) and paclitaxel on tumor
inhibition has been observed in vitro
and in vivo, especially for cells that are
resistant to paclitaxel. In paclitaxel-resis-
tant SKOV3TR cells, which do not
respond to paclitaxel-induced G2/M ar-
rest, addition of R406 with paclitaxel
retards cells in the G2/M phase and
potentiates cell apoptosis. Consistently,
combination of R406 and paclitaxel de-8 Cancer Cell 28, July 13, 2015 ª2015 Elsevicreases tumor growth in naive and recur-
rent xenograft tumor after continuous
paclitaxel treatment.
Tumor cells present diverse microtu-
bule-dependent and -independent
mechanisms to develop paclitaxel resis-
tance (Figure 1). To elucidate the molec-
ular mechanisms by which SYK inhibition
enhances the cytotoxic effects of pacli-
taxel, Yu et al. (2015) investigated theer Inc.alteration of the phosphoproteome in
SKOV3TR cells upon R406 treatment.
Confirmed by the elevated levels in pacli-
taxel-resistant cell lines and xenografts,
SYK-mediated tyrosine phosphorylation
of microtubule associated proteins
(MAP1B and MAP4) and a-tubulin have
been suggested as the primary resistant
mechanisms to counteract paclitaxel.
Potentially through the restoration of the
impaired binding affinity of the tyrosine
phosphorylated microtubule-associated
proteins, SYK inhibition has been
demonstrated to directly stabilize tubulin
polymers in the presence of paclitaxel in
various paclitaxel resistant ovarian can-
cer cells in which paclitaxel alone only
presents a minimal microtubule stabiliz-
ing effect. Therefore, Yu et al. (2015)
have suggested a novel anti-tumor
mechanism of SYK inhibition by aug-
menting the cytotoxicity of paclitaxel
through modulating the microtubule dy-
namics (Figure 1).
What is exciting about this report is that
several specific small molecule inhibitors
of SYK, such as fostamatinib/tamatinib
(R788/R406), have been developed as
orally administrable and highly tolerable
reagents. Their safety and efficacy have
been extensively demonstrated through
multiple phase I/II clinical trials to treat
inflammatory and autoimmune disorders
(such as rheumatoid arthritis and asthma)
as well as cancer (non-Hodgkin’s lym-
phoma and chronic lymphocytic leuke-
mia) (Geahlen, 2014). The identification
of SYK in acquired paclitaxel resistance
extends the potential application of these
molecules. Minimal toxicity has been
observed in mice treated with R406 and
paclitaxel at the effective synergistic
dosages. These encouraging observa-
tions demand the clinical investigation
of SYK inhibition to re-sensitize ovarian
cancer relapses to paclitaxel and there-
fore improve the overall survival of
ovarian cancer patients.
REFERENCES
Bhat, K.M.R., and Setaluri, V. (2007). Clin. Cancer
Res. 13, 2849–2854.
Geahlen, R.L. (2014). Trends Pharmacol. Sci. 35,
414–422.
Jayson, G.C., Kohn, E.C., Kitchener, H.C., and Le-
dermann, J.A. (2014). Lancet 384, 1376–1388.
Jinawath, N., Vasoontara, C., Jinawath, A., Fang,
X., Zhao, K., Yap, K.L., Guo, T., Lee, C.S., Wang,
Cancer Cell
PreviewsW., Balgley, B.M., et al. (2010). PLoS ONE 5,
e11198.
Mariani, M., Karki, R., Spennato, M., Pandya, D.,
He, S., Andreoli, M., Fiedler, P., and Ferlini, C.
(2015). Gene 563, 109–114.
Murray, S., Briasoulis, E., Linardou, H., Bafalou-
kos, D., and Papadimitriou, C. (2012). Cancer
Treat. Rev. 38, 890–903.Poruchynsky, M.S., Giannakakou, P., Ward, Y.,
Bulinski, J.C., Telford, W.G., Robey, R.W., and
Fojo, T. (2001). Biochem. Pharmacol. 62, 1469–
1480.
Prinos, P., Garneau, D., Lucier, J.-F., Gendron, D.,
Couture, S., Boivin, M., Brosseau, J.-P., Lapointe,
E., Thibault, P., Durand, M., et al. (2011). Nat.
Struct. Mol. Biol. 18, 673–679.Cancer CXiao, H., Wang, H., Zhang, X., Tu, Z., Bulinski, C.,
Khrapunovich-Baine, M., Hogue Angeletti, R.,
and Horwitz, S.B. (2012). ACS Chem. Biol. 7,
744–752.
Yu, Y., Gailllard, S., Phillip, J.M., Huang, T.-C.,
Pinto, S.M., Tessarollo, N.G., Zhang, Z., Pandey,
A., Wirtz, D., Ayhan, A., Davidson, B., et al.
(2015). Cancer Cell 28, this issue, 82–96.Genetic Classification of Gliomas:
Refining HistopathologyMichael B. Foote,1,2,3 Nickolas Papadopoulos,1,2,3 and Luis A. Diaz, Jr.1,2,3,*
1The Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA
2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
3The Ludwig Center for Cancer Genetics and Therapeutic at Johns Hopkins, Baltimore, MD 21287, USA
*Correspondence: ldiaz1@jhmi.edu
http://dx.doi.org/10.1016/j.ccell.2015.06.014
Newly published studies validate prior reports that specific combinations of genetic alternations in IDH1/2,
ATRX, TERT, TP53, and co-deletion of 1p/19q have the ability to reclassify gliomas into rational subsets,
defining a glioma’s biological and clinical behavior more accurately than stratifications based solely on
histopathology.Gliomas, which include astrocytomas,
oligodedrogliomas, oligoastrocytomas,
and glioblastomas (GBMs), are identified
and treated based on common histo-
pathological criteria. However, these
criteria may not accurately predict clinical
outcome because assessment methods
currently used in the clinic are overly
subjective, inconsistent, and possess
little power to distinguish the mixed
histological appearance of glioma tissue
(Olar and Sulman, 2015). Up to 43%
of neuro-oncology case reviews utilizing
histopathology for glial tumor identifi-
cation result in some degree of disagree-
ment, 9% of which have documented
serious clinical consequences resulting
from this uncertainty (Bruner et al., 1997).
Over the past decade, large-scale ge-
netic sequencing efforts have identified
key genomic alterations across glial
subtypes, including mutations in CIC,
FUBP1, 1p/19q co-deletion, IDH1/2,
TERT, ATRX, and the alternative length-
ening of telomeres (ALT) phenotype. The
FUBP1 and CIC mutations, recently iden-
tified in oliodendrogliomas, correspond
to chromosome 1p and 19q, respectively,and may represent key tumor suppres-
sors uncovered by loss of heterozygosity
(LOH) or co-deletion at 1p/19q (Bette-
gowda et al., 2011). Individually, each
somatic alteration has demonstrated
prognostic value in gliomas and other
tumor types (Jenkins et al., 2006; Parsons
et al., 2008; Bettegowda et al., 2011;
Killela et al., 2013).
In 2012, Jiao et al. were the first to
integrate these markers into a classifi-
cation model across adult gliomas (Jiao
et al., 2012). This initial model classified
gliomas by assessing the mutation sta-
tus of IDH, ATRX, and CIC/FUBP1,
correlating the genetic information
with histopathologic data and clinical
outcome, and ultimately partitioned gli-
omas into subgroups based on shared
genetic and clinical characteristics.
Three subgroups emerged from this
initial observation. Group 1 tumors
were characterized by mutations in
IDH1 and ATRX and mainly demon-
strated an astrocytoma phenotype
on histopathology. Group 2 tumors
harbored mutation in IDH1, CIC, and
FUBP1; the majority demonstrated oli-godendroglioma histology. Finally, group
3 tumors were wild-type for IDH and
ATRX and were consistent with grade
IV GBM histology. Patients with group
1 tumors demonstrated a median sur-
vival of 4.3 years, patients with group 2
tumors had a median survival of 8 years,
and patients suffering with gliomas of
the group 3 genotype had a median sur-
vival of 1.1 years.
In 2013, the discovery of promoter
mutations in TERT in large numbers of
gliomas led to a more refined classifica-
tion (Killela et al., 2013). TERT promoter
mutations were found in 83% of primary
glioblastomas and were mutually exclu-
sive with ATRX mutations and the ALT
phenotype, which was most evident
in astrocytomas (Killela et al., 2013).
Furthermore, the ALT phenotype and
ATRX mutations were found to be
strongly linked in virtually all cases,
suggesting a strong biologic correlation
between disruption of ATRX and ALT.
These data also provided supported
the notion that telomere maintenance
was an important feature of many gli-
omas and that two mutually exclusiveell 28, July 13, 2015 ª2015 Elsevier Inc. 9
